Clinical Trial Update: 16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients [Phase 3]

View source ↗

Summary

Phase 3 trial update reports 16-week efficacy and 3-year safety, tolerability, and efficacy of secukinumab in active ankylosing spondylitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Spondylitis, Ankylosing | Phase 3 | Status: COMPLETED | Results posted: 2018-12-12